A Tissue-Targeted Immunotherapy Protects Against Recurrent Ocular Herpes Infection and Disease, and Alleviates the Associated Cognitive, Behavioral, and Social Deficits in a 'Humanized' HLA Transgenic Mouse Model of UVB-Induced Reactivation
Entry updated:
A mouse study tested a T-cell immunotherapy for recurrent HSV-1 eye disease, delivering HSV-1 epitopes by a topical ocular AAV8 vector to mice that were already latently infected. The authors report protection against recurrent disease and better survival after UVB-induced reactivation, with HSV-1-specific T cells accumulating in the cornea and trigeminal ganglia. The authors say the findings support translational potential in humans; the work itself was done in mice.
The immunotherapy was given to mice already latently infected with HSV-1, so the design is therapeutic rather than preventive. Its epitopes come from HSV-1 gD/gB, tegument proteins and the helicase UL9. Protection was reported for the full combination, unlike its individual components.
The T cells were found in the cornea and trigeminal ganglia but not in the spleen. The authors also report improved spatial memory, less depression-like behavior and reversed social withdrawal in mice with recurrent ocular herpes. The authors state that no ocular herpes vaccine or immunotherapy currently exists.
These are animal results, and the authors describe human translational potential as a possibility rather than a finding.
Sources
How this entry was checked
This entry was drafted with AI assistance and then checked. Every statement below was matched, word for word, to a passage in the abstract of the source by software (7 passages and 2 numbers traced). A separate AI pass, run independently and shown only the source and the statements, then tried to find errors (supported by the source, Oct 3, 2026). The editor (Mark) read and approved it on Oct 12, 2026. This is an editorial check, not peer review.
- HSV-1 epitopes were delivered with a topical ocular AAV8 vector to mice that were already latently infected and carried human HLA genes.
- The immunotherapy uses T-cell epitopes from HSV-1 glycoproteins, tegument proteins and the helicase UL9.
- The authors report protection against recurrent HSV-1 disease and better survival after UVB-induced reactivation, which the individual components did not match.
- HSV-1-specific T cells accumulated in the cornea and trigeminal ganglia but not in the spleen.
- The authors report improved spatial memory, less depression-like behavior and reversed social withdrawal in mice with recurrent ocular herpes.
- The authors state that no ocular herpes vaccine or immunotherapy currently exists.
- The authors say the findings support translational potential in humans.